AIMS: To develop an approach for the effective treatment of ovarian tumor, prevention of metastases and limitation of side effects. MATERIALS & METHODS: In order to combine chemotherapy with genotherapy, we constructed a nanoscale-based tumor-targeted system containing two anticancer drugs, two antisense oligonucleotides (suppressors of cellular resistance) and a ligand specific to receptors overexpressed in cancer cells. The system was tested in a mouse metastatic xenograft model using tumor isolates from patients with ovarian carcinoma. RESULTS: Treatment with the proposed nanosystem decreased primary tumor, prevented intraperitoneal metastases and limited adverse side effects. CONCLUSIONS: The advantages of the proposed targeted complex treatment of primary aggressive ovarian tumor and prevention of metastases make the proposed approach promising for clinical applications.
AIMS: To develop an approach for the effective treatment of ovarian tumor, prevention of metastases and limitation of side effects. MATERIALS & METHODS: In order to combine chemotherapy with genotherapy, we constructed a nanoscale-based tumor-targeted system containing two anticancer drugs, two antisense oligonucleotides (suppressors of cellular resistance) and a ligand specific to receptors overexpressed in cancer cells. The system was tested in a mouse metastatic xenograft model using tumor isolates from patients with ovarian carcinoma. RESULTS: Treatment with the proposed nanosystem decreased primary tumor, prevented intraperitoneal metastases and limited adverse side effects. CONCLUSIONS: The advantages of the proposed targeted complex treatment of primary aggressive ovarian tumor and prevention of metastases make the proposed approach promising for clinical applications.
Authors: Perry T Yin; Shreyas Shah; Nicholas J Pasquale; Olga B Garbuzenko; Tamara Minko; Ki-Bum Lee Journal: Biomaterials Date: 2015-11-12 Impact factor: 12.479
Authors: Jose Portilla-Arias; Rameshwar Patil; Hui Ding; Julia Y Ljubimova; Satoshi Inoue; Janet L Markman; Arthur Rekechenetskiy; Bindu Konda; Pallavi R Gangalum; Alexandra Chesnokova; Alexander V Ljubimov; Keith L Black; Eggehard Holler Journal: J Drug Target Date: 2013-09-16 Impact factor: 5.121
Authors: Vatsal Shah; Oleh Taratula; Olga B Garbuzenko; Olena R Taratula; Lorna Rodriguez-Rodriguez; Tamara Minko Journal: Clin Cancer Res Date: 2013-09-13 Impact factor: 12.531